CLRB

CLRB

USD

Cellectar Biosciences Inc. Common Stock

$3.510+0.020 (0.573%)

Prix en Temps Réel

Healthcare
Biotechnologie
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$3.490

Haut

$3.560

Bas

$3.465

Volume

0.02M

Fondamentaux de l'Entreprise

Capitalisation Boursière

11.2M

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

0.19M

Bourse

NCM

Devise

USD

Intervalle sur 52 Semaines

Bas $3.17Actuel $3.510Haut $66

Actualités Connexes

GlobeNewswire

Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma

FLORHAM PARK, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of

Voir plus
Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma
GlobeNewswire

Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research

FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of

Voir plus
Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research
GlobeNewswire

Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million

FLORHAM PARK, N.J., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) ("Cellectar" or the "company"), a late-stage biotechnology company focused on the discovery and development of drugs for

Voir plus
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.